Journal of Neuro-Oncology

, Volume 107, Issue 1, pp 191–196 | Cite as

Central nervous system metastases from castration-resistant prostate cancer in the docetaxel era

  • Orazio CaffoEmail author
  • Angela Gernone
  • Cinzia Ortega
  • Teodoro Sava
  • Giacomo Cartenì
  • Gaetano Facchini
  • Giovanni Lo Re
  • Placido Amadio
  • Roberto Bortolus
  • Vincenzo Pagliarulo
  • Veronica Prati
  • Antonello Veccia
  • Enzo Galligioni
Clinical Study – Patient Study


Central nervous system (brain or leptomeningeal) metastases (BLm) are considered rare in castration-resistant prostate cancer (CRPC) patients. Now that docetaxel has become the reference drug for first-line treatment of CRPC, patients whose disease is not controlled by hormonal manipulations may live much longer than before and have higher risk of developing BLm. We retrospectively reviewed the records of all patients with CRPC attending our centres from 2002 to 2010, and identified all of those who were diagnosed as having BLm and received (or were considered to have been eligible to receive) docetaxel-based treatment. We identified 31 cases of BLm (22 brain metastases and 9 leptomeningeal metastases) with an incidence of 3.3%. BLm-free survival was 43.5 months, and survival after BLm discovery was 4 months. With six patients surviving for more than 1 year after developing BLm, the projected 1-year BL-S rate was 25.8%. The findings of our study may be relevant in clinical practice as they indicate that incidence of BLm in CRPC patients in the docetaxel era seems to be higher than in historical reports, meaning that special attention should be paid to the appearance of neurological symptoms in long-term CRPC survivors because they may be related to BLm.


Castration-resistant prostate cancer Brain metastases Leptomeningeal metastases Docetaxel Chemotherapy 


Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300PubMedCrossRefGoogle Scholar
  2. 2.
    Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:765–781PubMedCrossRefGoogle Scholar
  3. 3.
    Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 17:2506–2513PubMedGoogle Scholar
  4. 4.
    Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756–1764PubMedGoogle Scholar
  5. 5.
    Martel CL, Gumerlock PH, Meyers FJ, Lara PN (2003) Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev 29:171–187PubMedCrossRefGoogle Scholar
  6. 6.
    Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512PubMedCrossRefGoogle Scholar
  7. 7.
    Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520PubMedCrossRefGoogle Scholar
  8. 8.
    Fitzpatrick JM, Sternberg CN, Saad F, Extermann M, Caffo O, Halabi S, Kramer G, Oudard S, de Wit R (2009) Treatment decisions for advanced genitourinary cancers: from symptoms to risk assessment. Eur Urol Suppl 8:738–746CrossRefGoogle Scholar
  9. 9.
    Eymard JC, Oudard S, Gravis G, Ferrero JM, Theodore C, Joly F, Priou F, Krakowski I, Zannetti A, Thill L, Beuzeboc P (2010) Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int 106:974–978PubMedCrossRefGoogle Scholar
  10. 10.
    Mongan JP, Fadul CE, Cole BF, Zaki BI, Suriawinata AA, Ripple GH, Tosteson TD, Pipas JM (2009) Brain metastases from colorectal cancer: risk factors, incidence, and the possible role of chemokines. Clin Colorectal Cancer 8:100–105CrossRefGoogle Scholar
  11. 11.
    Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972–2977PubMedCrossRefGoogle Scholar
  12. 12.
    Gavrilovic IT, Posner JB (2005) Brain metastases: epidemiology and pathophysiology. J Neurooncol 75:5–14PubMedCrossRefGoogle Scholar
  13. 13.
    McCutcheon IE, Eng DY, Logothetis CJ (1999) Brain metastasis from prostate carcinoma: antemortem recognition and outcome after treatment. Cancer 86:2301–2311PubMedCrossRefGoogle Scholar
  14. 14.
    Tremont-Lukats IW, Bobustuc G, Lagos GK, Lolas K, Kyritsis AP, Puduvalli VK (2003) Brain metastasis from prostate carcinoma: the M. D. Anderson Cancer Center experience. Cancer 98:363–368PubMedCrossRefGoogle Scholar
  15. 15.
    Salvati M, Frati A, Russo N, Brogna C, Piccirilli M, D’Andrea G, Occhiogrosso G, Pichierri A, Caroli E (2005) Brain metastasis from prostate cancer. Report of 13 cases and critical analysis of the literature. J Exp Clin Cancer Res 24:203–207PubMedGoogle Scholar
  16. 16.
    Catane R, Kaufman J, West C, Merrin C, Tsukada Y, Murphy GP (1976) Brain metastasis from prostatic carcinoma. Cancer 38:2583–2587PubMedCrossRefGoogle Scholar
  17. 17.
    Taylor HG, Lefkowitz M, Skoog SJ, Miles BJ, McLeod DG, Coggin JT (1984) Intracranial metastases in prostate cancer. Cancer 53:2728–2730PubMedCrossRefGoogle Scholar
  18. 18.
    Lin C, Turner S, Gurney H, Peduto A (2008) Increased detections of leptomeningeal presentations in men with hormone refractory prostate cancer: an effect of improved systemic therapy? J Med Imaging Radiat Oncol 52:376–381PubMedCrossRefGoogle Scholar
  19. 19.
    Roberts-Thomson R, Rosenthal MA, Gonzales M, Drummond K (2009) Brain metastases in hormone refractory prostate cancer: a changing natural history? Intern Med J 39:205–206PubMedCrossRefGoogle Scholar
  20. 20.
    Crivellari D, Pagani O, Veronesi A, Lombardi D, Nole F, Thurlimann B, Hess D, Borner M, Bauer J, Martinelli G, Graffeo R, Sessa C, Goldhirsch A (2001) High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol 12:353–356PubMedCrossRefGoogle Scholar
  21. 21.
    van der Veldt AAM, Hendrikse NH, Smit EF, Mooijer MP, Rijnders AY, Gerritsen WR, van der Hoeven JJ, Windhorst AD, Lammertsma AA, Lubberink M (2010) Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients. Eur J Nucl Med Mol Imaging 37:1950–1958PubMedCrossRefGoogle Scholar
  22. 22.
    Sanson M, Napolitano M, Yaya R, Keime-Guibert F, Broet P, Hoang-Xuan K, Delattre JY (2000) Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study. J Neurooncol 50:245–249PubMedCrossRefGoogle Scholar
  23. 23.
    Sissung TM, Baum CE, Deeken J, Price DK, Ragon-Ching J, Steinberg SM, Dahut W, Sparreboom A, Figg WD (2008) ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res 14:4543–4549PubMedCrossRefGoogle Scholar
  24. 24.
    Cordon-Cardo C, O’Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86:695–698PubMedCrossRefGoogle Scholar
  25. 25.
    Schinkel AH, Smit JJ, Van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP, Berns AJM, Borst P (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491–502PubMedCrossRefGoogle Scholar
  26. 26.
    de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154PubMedCrossRefGoogle Scholar
  27. 27.
    Cisternino S, Bourasset F, Archimbaud Y, Semiond D, Sanderink G, Scherrmann JM (2003) Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. Br J Pharmacol 138:1367–1375PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  • Orazio Caffo
    • 1
    Email author
  • Angela Gernone
    • 2
  • Cinzia Ortega
    • 3
  • Teodoro Sava
    • 4
  • Giacomo Cartenì
    • 5
  • Gaetano Facchini
    • 6
  • Giovanni Lo Re
    • 7
  • Placido Amadio
    • 8
  • Roberto Bortolus
    • 9
  • Vincenzo Pagliarulo
    • 10
  • Veronica Prati
    • 11
  • Antonello Veccia
    • 1
  • Enzo Galligioni
    • 1
  1. 1.Department of Medical OncologySanta Chiara HospitalTrentoItaly
  2. 2.Department of Medical OncologyCivil HospitalBariItaly
  3. 3.Department of Medical OncologyInstitute for Cancer Research and TreatmentCandioloItaly
  4. 4.Department of Medical Oncology dOMaggiore HospitalVeronaItaly
  5. 5.Department of Medical OncologyCardarelli HospitalNaplesItaly
  6. 6.Medical Oncology Division – Uro-Gynaecological DepartmentNational Cancer Institute of NapoliNaplesItaly
  7. 7.Department of Medical OncologySanta Maria degli Angeli HospitalPordenoneItaly
  8. 8.Department of Medical OncologyGaribaldi HospitalCataniaItaly
  9. 9.Department of Radiotherapy OncologyNational Cancer InstituteAvianoItaly
  10. 10.Department of UrologyUniversity of BariBariItaly
  11. 11.Department of Medical OncologyInstitute for Cancer Research and TreatmentCandioloItaly

Personalised recommendations